PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12481819

Inhaled nitric oxide.

William E Hurford
View original source ↗Export metadata ↓

Abstract

Inhaled NO offers a novel therapy for the treatment of pulmonary hypertensive diseases and the symptomatic relief of hypoxemia. The use of iNO reduces the necessity for ECMO in newborns and infants with acute hypoxemic respiratory failure. Proper indications, contraindications, dosing criteria, and implications of the toxic actions of NO must be delineated fully. Randomized clinical trials of patients with carefully defined, specific acute disease states that are characterized by pulmonary hypertension or hypoxemia have not been completed.

Explore related subjects

Administration, InhalationAnimalsClinical Trials as TopicHumansHypertension, PulmonaryInfantInfant, NewbornNitric OxideRespiratory Distress Syndrome, NewbornTreatment OutcomeVasodilator AgentsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

William E Hurford. 2002. Inhaled nitric oxide.. https://doi.org/10.1016/s1078-5337(02)00008-4

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗
PubMed2007

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗